Company intelligence / Profile preview
Eskayef Pharmaceuticals Limited
Dhaka, Bangladeshskfbd.com ↗
- Ownership
- Private
- Employees
- ~987
- Development stage
- Commercial
01
Overview
Eskayef has received US FDA approval for both solid and injectable pharmaceutical products. They have successfully developed and marketed generic versions of COVID-19 treatments including Remdesivir (Remivir), Molnupiravir (Monuvir), and Nirmatrelvir with Ritonavir (Paxovir).
- Therapeutic areas
- GastroenterologyOphthalmologyNeurologyInfectious Diseases
- Modalities
- Small moleculesgeneric drugsinjectable pharmaceuticalsoral formulations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Allergan (for LUMIGAN/bimatoprost)
Beyond the preview
Go deeper on Eskayef Pharmaceuticals Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eskayef Pharmaceuticals Limited.